TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06177132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIS-REHAB protocol
Description: The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasises gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
Study: NCT06007534

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, urine samples and oropharyngeal swabs before taking 200mg of doxycycline and then 2h, 24h, 48h, 7 days, 14 days, 60 days and 90 days after the single dose of doxycycline Hair samples: at the time of doxycycline administration, 1 month and 3 months after the single dose of doxycycline
Study: NCT06518824

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS On
Description: The DBS device will be turned on while the patient undergoes the working memory task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS On
Description: The DBS device will be turned on while the patient undergoes the working memory task.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS On
Description: The DBS device will be turned on while the patient undergoes the working memory task.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS Off
Description: The DBS device will be turned off while the patient undergoes the working memory task.
Study: NCT06182137

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.
Study: NCT05817890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadraciclib
Description: Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
Study: NCT05942586

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsule (L. reuteri PB-W1™), Placebo sachet
Description: Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic sachet (Prebiotic Blend), Placebo capsule
Description: Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)
Description: Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet, Placebo capsule
Description: Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
Study: NCT05253209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Intravenous L-citrulline given for up to 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte A
Description: Intravenous Plasmalyte A given for up to 48 hours
Study: NCT05695950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: GLPG3667 capsules will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG3667
Description: GLPG3667 capsules will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
Study: NCT05989230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
Study: NCT06548126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Parenting Program
Description: Online Parenting Program comprised of 12 online modules. Caregivers do one module per week for 12-15 weeks; each unit takes about 20 minutes to do. The Caregiver also practices the tools they learn for Parenting their Children between sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No online parenting program
Description: List of Parenting resources.
Study: NCT06224205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
Study: NCT05684055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line antihypertensive single-pill combination (SPC)
Description: In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized counselling and referral to the closest health facility
Description: In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
Study: NCT05682625

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06423885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration for a cycle of 3 weeks.
Study: NCT04817670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 120 mg
Description: Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 360 mg
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 240 mg
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study: NCT05702463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab twice daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 40Mg Chew Tab twice daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg EC Tab once daily for 7 days
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
Study: NCT05642741

Intervention type: OTHER
Intervention: Response to medical and research questionnaires
Description: Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
Study: NCT06330805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo functional fitness tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo functional fitness tests

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study: NCT06639594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
Study: NCT05007405

Intervention type: OTHER
Intervention: Groups/Cohortes
Description: Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
Study: NCT05322343

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety.
Study: NCT05403112

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone ring with open sinus lifting
Description: All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
Study: NCT05322343

Intervention type: OTHER
Intervention: Fasting blood sampling.
Description: In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.

Intervention type: OTHER
Intervention: Saliva collection and nasal or nasopharyngeal swab
Description: On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.

Intervention type: OTHER
Intervention: Urine samples
Description: During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.

Intervention type: OTHER
Intervention: Hair and a tonenail (or hand nail) sampling
Description: During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope

Intervention type: OTHER
Intervention: Nasal microbiota
Description: Nasal or nasopharyngeal swab

Intervention type: OTHER
Intervention: Measurements
Description: In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes.

Intervention type: OTHER
Intervention: Neuroimaging
Description: A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed

Intervention type: OTHER
Intervention: Medical visit
Description: For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
Study: NCT05916339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication
Description: Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Description: If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Study: NCT05478850

Intervention type: PROCEDURE
Intervention: radiotherapy under anesthesia
Description: Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
Study: NCT04309734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-777
Description: Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-777
Description: Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-777
Description: Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, as one or two placebo capsules, depending on the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
Study: NCT06220435

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiotherapy regimen.
Description: * Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions
Study: NCT05130008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally-enabled CHW Care
Description: Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual CHW Care
Description: Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
Study: NCT05632042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification (exercise and control of diet)
Description: erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
Study: NCT05506384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaps Preventions Therapy
Description: The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
Study: NCT06458283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hiybrid simulation
Description: The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control grup
Description: low fidelity simulator